Trial
NCT03237377
Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
AstraZeneca
Condition
Non-Small Cell Lung Cancer
Intervention
Durvalumab
Why stopped
low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-27